Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jerome Stevens' $1.3 Bil. Levothyroxine Suit Against FDA Dismissed

This article was originally published in The Pink Sheet Daily

Executive Summary

D.C. federal court rules that FDA acted within its authority to extend the deadline to review levothyroxine products. Damage from FDA's release of confidential information related to Jerome Stevens' Unithroid NDA was not demonstrated to be separate from that of the deadline extension.

You may also be interested in...



Levothyroxine Approval Standards For ANDAs, Brands Should Be Consistent, Jerome Stevens Says

Generics should demonstrate same dose consistency as 505(b)(2) applications, the company says. Jerome Stevens requests guidance clarifying ANDA review standards and asks FDA to consider pulling Mylan’s Unithroid generic.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale

Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel